Several drugs and regimens, such as dacarbazine, topotecan, liposomial irinotecan + 5-fluorouracil, docetaxel, and the addition of bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), to FOLFIRI, failed to prove beneficial in GEP-NEC patients [46,47,48,49]. Here, VEGFA is linked to neuroendocrine carcinoma.